CHICAGO and BOSTON, July 6,
2021 /PRNewswire/ -- GE Healthcare and SOPHiA
GENETICS today announced that they have signed a letter of
intent to collaborate on advancing cancer care, with the goal of
better targeting and matching treatments to each patient's genomic
profile and cancer type, helping to ensure the most effective and
personalized treatment.
The companies aim to develop new artificial intelligence
(AI)-powered analytics and workflow solutions to serve both the
clinical and biopharma markets. They'll be deploying GE
Healthcare's extensive medical imaging and monitoring capabilities
and Edison platform-enabled data aggregation with the SOPHiA DDM™
cloud-based software-as-a-service analytics genomic insights
platform and related solutions, which are available in more than
750 hospitals, laboratories and biopharma companies.
GE Healthcare has deep expertise in clinical workflows, deep
learning AI algorithms for image reconstruction and image
segmentation, analytics and standardization, while SOPHiA GENETICS
is a pioneer in data-driven medicine. Their cloud-based
software-as-a-service analytics platform uses AI and machine
learning to generate actionable insights for clinicians and
researchers from complex multimodal datasets. The companies aim to
break down the data silos across instruments and sites that so
often delay or even prevent patients from getting the most
appropriate treatment both in cancer and in other diseases.
As cases of cancer continue to rise and are predicted to reach
29.5 million new cases per year by 2040,1 there is a
growing demand for data-driven medicine, both for clinical practice
and clinical trials. GE Healthcare is utilizing its Edison platform
to integrate data from diverse sources, such as electronic health
records (EHR) and radiology information systems (RIS), imaging and
other medical device data. This integrated data can be used to
develop and deploy AI enabled solutions to help simplify oncology
patient workflows, better understand increasingly complicated
clinical patient data, and compare data from patient to
patient.
"The integration of genomics-based artificial intelligence into
oncology workflow solutions would be a major breakthrough for
integrated cancer medicine and for future clinical research, which
increasingly depend on the ability to select those patients most
likely to respond to new therapies," said Jan Makela, President & CEO, Imaging at GE
Healthcare. "This collaboration represents another step
in GE Healthcare's vision of making precision health—more efficient
and personalized care—a reality."
"By bringing together our global platform and insights-sharing
network with GE Healthcare's international reach and cutting-edge
products, healthcare professionals will be able to leverage their
expertise and work together for the benefit of patients all over
the world. Cancer patients will be able to receive equal access to
better diagnoses and treatments through secure data pooling and
knowledge sharing, unlocking the promise of data-driven medicine at
scale," said Jurgi Camblong, co-founder and CEO, SOPHiA GENETICS.
Next-generation sequencing (NGS) is rapidly becoming a new
standard of care in cancer diagnostics, particularly as novel
therapies require genomic information to be prescribed in a
personalized way. Today, these sets of information and insights are
often bespoke and difficult for clinicians to easily and quickly
obtain and recall along the patient care journey.
About GE Healthcare:
GE Healthcare is the $18 billion
healthcare business of GE (NYSE: GE). As a leading global medical
technology, pharmaceutical diagnostics and digital solutions
innovator, GE Healthcare enables clinicians to make faster, more
informed decisions through intelligent devices, data analytics,
applications and services, supported by its Edison intelligence
platform. With over 100 years of healthcare industry experience and
around 50,000 employees globally, the company operates at the
center of an ecosystem working toward precision health, digitizing
healthcare, helping drive productivity and improve outcomes for
patients, providers, health systems and researchers around the
world.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the
latest news, or visit our website www.gehealthcare.com for more
information.
About SOPHiA GENETICS:
SOPHiA GENETICS is a healthcare technology company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
more than 750 hospital, laboratory and biopharma institutions
globally.
More info: SOPHiAGENETICS.COM; follow @SOPHiAGENETICS on
Twitter.
Forward-Looking Statements
Certain statements made in this press release are
"forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements may be identified by
the use of words such as "anticipate," "believe," "expect,"
"estimate," "plan," "outlook" and "intend" and other similar
expressions that predict or indicate future events or trends or
that are not statements of historical matters. These
forward-looking statements reflect the current analysis of existing
information and are subject to various risks and uncertainties. As
a result, caution must be exercised in relying on forward looking
statements. Due to known and unknown risks, actual results may
differ materially from GE's or SOPHiA GENETICS' expectations or
projections. The following factors, among others, could cause
actual results to differ materially from those described in these
forward-looking statements: the inability of the parties to
negotiate and execute definitive agreements, on terms consistent
with those in the letter of intent, or at all; the inability to
meet the objectives, goals and targets contemplated by the letter
of intent or any related definitive agreement; costs related to the
proposed collaboration; the current size and future growth, if any,
of the addressable market of the proposed collaboration, in
particular in the field of oncology, including the number of cases
of cancer; changes in applicable laws or regulations; other
economic, business and/or competitive factors; the effect of the
COVID-19 pandemic on the parties and their ability to enter into
and fulfil their respective obligations under any definitive
agreement; as well as the risks and uncertainties discussed from
time to time in other reports and other public filings with the
Securities and Exchange Commission by the parties, if any.
The forward-looking statements contained in this press
release are made as of the date of this press release, and neither
GE nor SOPHiA undertakes any obligation to update publicly or to
revise any of the included forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by securities law.
This press release shall not constitute an offer to sell or
the solicitation of an offer to buy any securities in any
jurisdiction.
Media Contact for GE Healthcare:
Hannah Huntly
Hannah.huntly@ge.com
Media Contact for SOPHiA
GENETICS:
Consort Partners
sophiagenetics@consortpartners.com
View original
content:https://www.prnewswire.com/news-releases/ge-healthcare-and-sophia-genetics-to-collaborate-to-match-treatments-to-multimodal-patient-data-and-cancer-type-301325781.html
SOURCE SOPHiA GENETICS